Collegium Pharma (COLL) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
Collegium Reports Third Quarter 2019 Financial Results
November 6, 2019 4:01 PM ESTNew Exclusive Formulary Wins Announced for Xtampza® ER Effective January 1, 2020 Covering More than 35 Million Lives
Xtampza® ER Net Product Revenues Were $26.5 Million in the Third Quarter of 2019, a 56% Increase Over the Third Quarter of 2018
Cash Increased by $5.1 Million, to $153.8 Million as of September 30, 2019
Conference Call Scheduled for Today at 4:30 p.m. ET
STOUGHTON, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) --... More
